Cited 12 times in
Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이용찬 | - |
dc.date.accessioned | 2016-02-04T10:56:31Z | - |
dc.date.available | 2016-02-04T10:56:31Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1590-8658 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/139318 | - |
dc.description.abstract | BACKGROUND: Declining of eradication rates for Helicobacter pylori in Korea may be partly from the increasing prevalence of antibiotic resistance, especially clarithromycin resistance. AIM: To compare the efficacy and the safety of using 10-day standard sequential therapy and levofloxacin-containing sequential therapy as a first-line treatment for Helicobacter pylori eradication in Korea. METHODS: A total of 200 patients with proven Helicobacter pylori infection randomly received 10-day standard sequential therapy (n = 100) or levofloxacin-containing sequential therapy (n = 100). The standard sequential therapy group received rabeprazole and amoxicillin for 5 days, followed by rabeprazole, clarithromycin, and metronidazole for 5 more days. The levofloxacin-containing sequential therapy group was treated with rabeprazole and amoxicillin for 5 days, followed by rabeprazole, levofloxacin, and metronidazole for 5 more days. RESULTS: Intention-to-treat eradication rates were 79.0% and 78.0% for groups of standard sequential and levofloxacin-containing sequential therapy, respectively (P = 0.863). Per-protocol eradication rates were 84.9% and 81.3%, respectively, for these two therapies (P = 0.498). There were no significant differences between the groups in regard to the eradication rates and adverse events. CONCLUSIONS: The 10-day levofloxacin-containing sequential regimen and the standard sequential regimen showed the similar eradication rates of Helicobacter pylori in Korea. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 114~118 | - |
dc.relation.isPartOf | DIGESTIVE AND LIVER DISEASE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Amoxicillin/therapeutic use* | - |
dc.subject.MESH | Anti-Bacterial Agents/therapeutic use* | - |
dc.subject.MESH | Breath Tests | - |
dc.subject.MESH | Clarithromycin/therapeutic use* | - |
dc.subject.MESH | Drug Resistance, Bacterial | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Helicobacter Infections/drug therapy* | - |
dc.subject.MESH | Helicobacter pylori | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Levofloxacin/therapeutic use* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Metronidazole/therapeutic use* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Proton Pump Inhibitors/therapeutic use* | - |
dc.subject.MESH | Rabeprazole/therapeutic use* | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Urea/analysis | - |
dc.title | Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Hyuk Lee | - |
dc.contributor.googleauthor | Sung Noh Hong | - |
dc.contributor.googleauthor | Byung-Hoon Min | - |
dc.contributor.googleauthor | Jun Haeng Lee | - |
dc.contributor.googleauthor | Poong-Lyul Rhee | - |
dc.contributor.googleauthor | Yong Chan Lee | - |
dc.contributor.googleauthor | Jae J. Kim | - |
dc.identifier.doi | 10.1016/j.dld.2014.10.014 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02988 | - |
dc.relation.journalcode | J00735 | - |
dc.identifier.eissn | 1878-3562 | - |
dc.identifier.pmid | 25467826 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S1590865814007592 | - |
dc.subject.keyword | Eradication | - |
dc.subject.keyword | Helicobacter pylori | - |
dc.subject.keyword | Levofloxacin | - |
dc.subject.keyword | Sequential therapy | - |
dc.contributor.alternativeName | Lee, Yong Chan | - |
dc.contributor.affiliatedAuthor | Lee, Yong Chan | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 47 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 114 | - |
dc.citation.endPage | 118 | - |
dc.identifier.bibliographicCitation | DIGESTIVE AND LIVER DISEASE, Vol.47(2) : 114-118, 2015 | - |
dc.identifier.rimsid | 45565 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.